Its seems a good product but not worth a cracker unless trials...

Its seems a good product but not worth a cracker unless trials prove its ok. So it remains for the time being high end spec.
The mistake was assuming it would be easy to obtain volunteers. Hind sight is perfect sight but there was a failure to plan properly.
The chart shows the SP was moving down before this news which gave downward momentum a big kick along.
Looks very short term oversold which may well see a short term bounce.
Until the market sees volunteers getting on board overall downward pressure will likely dominate.
The market lacks patience. I am holding through this hiccup and may top up if we hit lower support.
This is a nuisance but shiete happens in markets especially where planning is 2nd rate.
Its just wait now to see how the revised strategy works.